Investor Relations Home
Portola Pharmaceuticals was founded in 2003 and is headquartered in South San Francisco, Calif. We completed an initial public offering (IPO) in May 2013 and are traded on the Nasdaq Stock Market under the symbol PTLA. We have approximately 70 employees.More >>
|07/07/14||Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Daiichi Sankyo for Phase 3 Studies of Factor Xa Inhibitor Antidote, Andexanet Alfa, and Edoxaban|
|-- Phase 3 Collaboration Agreements in Place With All Direct Factor Xa Inhibitor Manufacturers While Portola Retains All Rights to Andexanet Alfa --
SOUTH SAN FRANCISCO, Calif., July 7, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that it has entered into a second clinical collaboration agreement with Daiichi Sankyo to study andexanet alfa, Portola's investigational Factor Xa inhibitor antidote, in Phase 3 registration studies with Daiichi Sankyo's Factor Xa... |
|06/12/14||Portola Pharmaceuticals to Present at the 2014 Wells Fargo Securities Healthcare Conference|
|SOUTH SAN FRANCISCO, Calif., June 12, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that William Lis, chief executive officer, will present at the 2014 Wells Fargo Securities Healthcare Conference on Wednesday, June 18, at 8:20 a.m. Eastern Time in Boston.
The presentation will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceutica... |
|06/11/14||Portola Pharmaceuticals Announces Positive Phase 2 Data With FDA-Designated Breakthrough Therapy Andexanet Alfa and Enoxaparin|
|--Data Extend the Potential for Andexanet as an Antidote Beyond
Oral Factor Xa Inhibitors to Injectible Low Molecular Weight Heparin--
SOUTH SAN FRANCISCO, Calif., June 11, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that a Phase 2 proof-of-concept study in healthy volunteers demonstrated that andexanet alfa, a potential first-in-class Factor Xa inhibitor antidote, immediately reversed the anticoagulation activity of enoxaparin, a low molecular we... |
|05/14/14||Portola Pharmaceuticals Announces Two Presentations of Data on Cerdulatinib, an Oral Dual Syk/JAK Inhibitor, at 2014 ASCO Annual Meeting|
|--Initial Phase 1 Doses Associated with High Levels of Syk and JAK Inhibition–
--Activity in Cell Lines with CARD11 Mutation May Further Differentiate Cerdulatinib--
SOUTH SAN FRANCISCO, Calif., May 14, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced two upcoming data presentations on cerdulatinib*, the Company's novel, oral, dual Syk-JAK kinase inhibitor, at the upcoming American Society of Clinical Oncology (ASCO) 50th Annual Meeting, which i... |
|05/12/14||Portola Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update|
|Conference Call Today at 4:30 p.m. ET
SOUTH SAN FRANCISCO, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today provided a corporate update and reported its financial results for the quarter ended March 31, 2014.
"We have had a very productive quarter, and we remain confident we can achieve our goal of bringing to market our three wholly-owned treatments for patients with blood clots and blood cancers," said William Lis, chief executive officer of Portola. "O... |
|There are currently no events scheduled.|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.